You have 9 free searches left this month | for more free features.

Fibroblast growth factor receptor 3 (FGFR3)

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Bladder Cancer Trial in Indianapolis, Baltimore, Rockledge (Dovitinib)

Terminated
  • Bladder Cancer
  • Indianapolis, Indiana
  • +2 more
Jul 7, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Phoenix, Arizona
  • +36 more
Jan 27, 2023

Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)

Withdrawn
  • Bladder Transitional Cell Carcinoma
  • +2 more
  • (no location specified)
Aug 8, 2022

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in

Recruiting
  • Locally Advanced Gastrointestinal Stromal Tumor
  • +7 more
  • Biopsy
  • +4 more
  • Duarte, California
  • +17 more
Feb 2, 2023

Cholangiocarcinoma Trial in China, Japan (E7090)

Active, not recruiting
  • Cholangiocarcinoma
  • Bengbu, Anhui, China
  • +55 more
Jan 24, 2023

Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)

Active, not recruiting
  • Squamous-cell Non-small Cell Lung Cancer
  • Baden, Switzerland
  • +10 more
Jan 20, 2022

Advanced or Recurrent Solid Tumors, FGFR Gene Alterations Trial in Japan (E7090)

Recruiting
  • Advanced or Recurrent Solid Tumors
  • FGFR Gene Alterations
  • Aoba-ku, Sendai, Miyagi, Japan
  • +4 more
May 9, 2022

Urinary Bladder Tumors, Receptors, Fibroblast Growth Factor Trial in Japan (Erdafitinib Intravesical Delivery System)

Not yet recruiting
  • Urinary Bladder Neoplasms
  • Receptors, Fibroblast Growth Factor
  • Erdafitinib Intravesical Delivery System
  • Kanagawa, Japan
  • +3 more
Jan 27, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Serum Insulin-like Growth Factor Binding Protein-3 asPotential

Not yet recruiting
  • Colorectal Cancer
  • evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer
  • (no location specified)
May 6, 2023

Advanced Cancer, Metastatic Cancer Trial in Canada, United States (LY3076226)

Completed
  • Advanced Cancer
  • Metastatic Cancer
  • Philadelphia, Pennsylvania
  • +3 more
Apr 9, 2020

Solid Tumours Trial in Worldwide (Debio1347 (CH5183284))

Terminated
  • Solid Tumours
  • Debio1347 (CH5183284)
  • Boston, Massachusetts
  • +7 more
Sep 8, 2020

Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

Active, not recruiting
  • Breast Neoplasms
  • Chuo Ku, Japan
  • +1 more
Dec 19, 2022

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer Trial (HER3-DXd)

Available
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
  • (no location specified)
Oct 17, 2023

Primary Breast Cancer Trial (SPECT)

Not yet recruiting
  • Primary Breast Cancer
  • (no location specified)
Jun 19, 2023

Advanced or Metastatic Solid Tumor Trial in Worldwide (Rogaratinib (BAY1163877), Copanlisib (BAY80-6946))

Completed
  • Advanced or Metastatic Solid Tumor
  • Rogaratinib (BAY1163877)
  • Copanlisib (BAY80-6946)
  • Los Angeles, California
  • +19 more
Jul 13, 2022

Breast Cancer Trial in Orange City (ARV-471 (PF-07850327), Palbociclib, Letrozole)

Recruiting
  • Breast Cancer
  • ARV-471 (PF-07850327)
  • +2 more
  • Orange City, Florida
    Mid Florida Hematology and Oncology Center
Jun 8, 2023

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

Recruiting
  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Sacituzumab Govitecan-hziy
  • +3 more
  • Marietta, Georgia
  • +1 more
Apr 21, 2023

Breast Cancer Female Trial in Tomsk ([99mTc]Tc-G3-(G3S)3C)

Enrolling by invitation
  • Breast Cancer Female
  • Tomsk, Russian Federation
    Olga
Jun 19, 2023

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

Pre-frail Elderly Trial in Jakarta (Cholecalciferol, Placebo)

Completed
  • Pre-frail Elderly
  • Jakarta, DKI Jakarta, Indonesia
    Cipto Mangunkusumo General Hospital
Jan 25, 2023